Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The use of adeno-associated virus (AAV) as a gene therapy vector has been approved recently for clinical use and has demonstrated efficacy in a growing number of clinical trials. However, the safety of AAV as a vector has been challenged by a single study that documented hepatocellular carcinoma (HCC) after AAV gene delivery in mice. Most studies have not noted genotoxicity following AAV-mediated gene delivery; therefore, the possibility that there is an association between AAV and HCC is controversial. Here, we performed a comprehensive study of HCC in a large number of mice following therapeutic AAV gene delivery. Using a sensitive high-throughput integration site-capture technique and global expressional analysis, we found that AAV integration into the RNA imprinted and accumulated in nucleus (Rian) locus, and the resulting overexpression of proximal microRNAs and retrotransposon-like 1 (Rtl1) were associated with HCC. In addition, we demonstrated that the AAV vector dose, enhancer/promoter selection, and the timing of gene delivery are all critical factors for determining HCC incidence after AAV gene delivery. Together, our results define aspects of AAV-mediated gene therapy that influence genotoxicity and suggest that these features should be considered for design of both safer AAV vectors and gene therapy studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“preclinical data suggest AAV integration events occur in a dose-dependent manner with a preference for integration at sites of active transcription, tissue-specific promoters are protective against oncogenesis.178, 179, 180”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [179]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · cited 1×
“GCGCGCTCGCTCG-3′) were trimmed by cutadapt (57).”
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool
Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480 · cited 2×
“Mouse BLAT (61, 62) (assembly December 2011 Genome Reference Consortium Mouse Build 38/mm10) was used to align the resultant sequence to the murine genome.”
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 1×
“To investigate this possibility, we developed a vector, AAV8-hAAT-synMUT, modeled on a AAV vector that had been administered to human subjects with hemophilia and did not cause genotoxicity in mice (13, 33).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 1×
“In fact, there are multiple human AAV gene therapy trials around the world that have been completed, are accruing participants, or are in preparation (4), and recent studies using AAV to treat 3 genetic disorders have been regarded as successful (5–8).”
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The most relevant example is the failure of animal studies to predict the increased risk for the development of leukemia after retroviral gene therapy for X-linked severe combined immunity deficiency (45).”
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 2×
“…the use of a more hepatotrophic serotype, such as AAV8 compared with AAV2, led to an increase in the rate of HCC. Additionally, the use of distinct capsids to pseudotype AAV vectors (48), such as serotypes 8 and 9, confers distinct patterns of tissue troph-ism in wild-type and disease states (49).”
Research works printed but not linked: 1
- Martin, 2011, EMBnetJ., 17
Cited by
Items 201–300 of 422
Kang, H., Gjorgjieva, M., Smith, S. N., Brooks, E. D., Chen, Z., Burgess, S. M., Chandler, R. J., Waskowicz, L. R., Grady, K. M., Li, S., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.016 · Cited by 21
“These studies implicated an rAAV-HCC locus in rodents, which stems from AAV integration in the Rian locus and the upregulation of the Rtl1 gene.(27,36) AAV integrations across the entire 58-kb Rian locus have been associated with HCC.”
BackgroundMethodResultSelf-citationRasmussen, C. L. M., Hede, E., Routhe, L. G., Körbelin, J., Helgudóttir, S. S., Thomsen, L. B., Schwaninger, M., Burkhart, A., & Moos, T. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15621 · Cited by 20
“…vector copy numbers was quantified postmortem in brain, heart, and lung tissue using qPCR. Liver samples were also included since previous studies have shown liver genotoxicity after injection with viral vectors (Chandler et al., 2015; Donsante et al., 2001; Nault et al., 2015; Rosas et al., 2012).”
MethodAdvances in viral vector-based delivery systems for gene therapy: a comprehensive review
Singh, K., Jain, D., Sethi, P., Gupta, J. K., Dubey, A., Noman, A. A., lal, S., Sharma, P., & Abdallah, E. M. (2025) · 3 Biotech · doi:10.1007/s13205-025-04366-7 · Cited by 24
“However, previous studies have shown that AAV vectors have a limited capacity for integration into the genome of animal models (Bella et al. 2020; Nault et al. 2015, 2016; Veron et al. 2012; Chandler et al. 2015; Donsante et al. 2007).”
Viral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 24
Integration and the risk of liver cancer—Is there a real risk?
Kasimsetty, A., & Sabatino, D. E. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.13915 · Cited by 21
“43 In addition, while the human genome lacks the Rian locus, overexpression of the orthologous loci DLK-DIO , is associated with poor prognosis in patients with HCC. 47 Notably, three highly expressed liver loci, Rian , albumin ( Alb ) and alpha-fetoprotein ( Afp ), are all more frequent targets of…”
BackgroundMethodInfluentialDelivery of DNA-Based Therapeutics for Treatment of Chronic Diseases
Sussman, C., Liberatore, R. A., & Drozdz, M. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040535 · Cited by 20
Singh, K., Fronza, R., Evens, H., Chuah, M., & VandenDriessche, T. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101365 · Cited by 19
“91 The number of AAV ISs in these studies was suf fi - cient to uncover clonal expansions and/or hepatocellular carcinoma of AAV-transduced liver cells.”
Genomics of Viral Hepatitis-Associated Liver Tumors
Péneau, C., Zucman‐Rossi, J., & Nault, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091827 · Cited by 22
Progress toward improved therapies for inborn errors of metabolism
Ginocchio, V. M., & Brunetti‐Pierri, N. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv418 · Cited by 23
“However, these findings were also observed more recently in MMA mice, which also developed HCC several months after neonatal AAV injections and showed vector integration and overexpression ofmicroRNA-341 (Mir341) proximal to the RNA imprinted and accumulated in nucleus (Rian) locus, in the same locus on chromosome 12…”
BackgroundPadula, A., Spinelli, M., Nusco, E., Cundin, X. B., Capolongo, F., Campione, S., Perna, C., Bastille, A., Ericson, M. N., Wang, C., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.171281 · Cited by 18
“AAV inoculation in newborn mice has been associated with the development of hepatocellular carcinoma (HCC) due to random AAV integration, with a mechanism involving transactivation by vector-borne promoter elements of multiple miRNAs embedded within the mouse Rian locus (26).”
BackgroundPreclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE
Parés, M., Fornaguera, C., Vila‐Julià, F., Oh, S., Fan, S. H. Y., Tam, Y. K., Comes, N., Vidal, F., Martí, R., Borrós, S., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.152 · Cited by 20
“21,22 Recent advances in the molecular tools that allow modifications of specific genomic sequences with very high efficiency are revolutionizing gene therapy and have raised interest in gene editing.”
Macdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 18
“96, 99 However, further larger studies using 695 mice and 132 mice, respectively, did not observe this phenomenon.”
InfluentialInteraction of vectors and parental viruses with the host genome
Gil-Fariña, I., & Schmidt, M. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.004 · Cited by 19
Mucopolysaccharidoses type I gene therapy
Hurt, S. C., Dickson, P., & Curiel, D. T. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12414 · Cited by 16
Advancements in Viral Gene Therapy for Gaucher Disease
Kulkarni, A., Chen, T., Sidransky, E., & Han, T. (2024) · Genes · doi:10.3390/genes15030364 · Cited by 24
“Thus, it is crucial to consider vector design with respect to possible undesirable integrations into the host genome to avoid carcinogenic outcomes [101].”
BackgroundCurrent and future prospects for hemophilia gene therapy
Ward, P., & Walsh, C. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1182859 · Cited by 18
“[69] provided answers to several of these questions in a long-term followup of gene-corrected mice.”
BackgroundSpadarella, G., Minno, A. D., Brunetti‐Pierri, N., Mahlangu, J. N., & Minno, G. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100737 · Cited by 19
Liver-directed gene-based therapies for inborn errors of metabolism
Piccolo, P., Rossi, A., & Brunetti‐Pierri, N. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1817375 · Cited by 16
“a locus in the mouse genome that is not conserved in humans [135,136].”
BackgroundHahn, P. A., & Martins, M. A. (2023) · Journal of Virus Eradication · doi:10.1016/j.jve.2023.100316 · Cited by 15
Lemmens, M., Dorsheimer, L., Zeller, A., & Dietz, Y. (2024) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2024.503767 · Cited by 16
Current and Emerging Issues in Adeno-Associated Virus Vector-Mediated Liver-Directed Gene Therapy
Piccolo, P., & Brunetti‐Pierri, N. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.179 · Cited by 17
“…persisting as an episome in the nucleus of transduced cells, the AAV genome can also integrate into the host genome in a dose-dependent manner 132,133 at an estimated frequency of 0.1 to 1 integration event per 100 cells in large animal models injected with doses ranging from 1 · 10 13 vg/kg to…”
InfluentialThompson, W. S., Mondal, G., VanLith, C. J., Kaiser, R. A., & Lillegard, J. B. (2020) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2020.1791082 · Cited by 15
Large-scale molecular epidemiological analysis of AAV in a cancer patient population
Qin, W., Xu, G., Tai, P. W. L., Wang, C., Luo, L., Li, C., Hu, X., Xue, J., Lü, Y., Zhou, Q., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01725-5 · Cited by 15
Gene therapy for hemophilia, a clinical viewpoint
Chou, S., Hsu, Y., & Lin, S. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.05.008 · Cited by 16
Alliegro, M., Ferla, R., Nusco, E., Leonibus, C. D., Settembre, C., & Auricchio, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.181 · Cited by 15
“Integration of vector DNA at highly transcribed loci has been associated with hepatocellular carcinoma (HCC) in mice 25, 29–33.”
InfluentialInsights into Gene Therapy for Urea Cycle Defects by Mathematical Modeling
Kok, C., Cunningham, S. C., Kuchel, P. W., & Alexander, I. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.053 · Cited by 16
“7 12 A one-compartment model of the urea cycle, previously developed by Kuchel et al. , 13,14 formed the starting point for the work described.”
Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis
Bu, F., Jia, P., Zhu, Y. Y., Yang, Y., Meng, H., Bi, Y., Huang, C., & Li, J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.009 · Cited by 14
“Notably, some studies have revealed that rAAV administration is related to the development of HCC in newborn mice, despite the fact that HCC was not observed in rAAV-treated adult mice and other mammals.(110,111) Therefore, long-term monitoring after rAAV-mediated gene delivery is important for evaluating potential ge…”
Venturoni, L. E., Chandler, R. J., Liao, J., Hoffmann, V. J., Ramesh, N., Gordo, S., Chau, N., & Venditti, C. P. (2022) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2022.06.011 · Cited by 14
Self-citationMuñoz-Melero, M., & Biswas, M. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.227 · Cited by 14
“For example, Duchenne muscular dystrophy (DMD) patients with deletions in exons 8–11 of the dystrophin gene over-lapping with those expressed in mini/microdystrophin may be at risk of developing transgene-specific T cell responses following AAV gene therapy (NCT04626674, NCT04281485, 2020-002093-27).”
Clinical perspective: Advancing hemophilia treatment through gene therapy approaches
Thornburg, C. D., PIPE, S. W., Cantore, A., Unzu, C., Jones, M., & Miesbach, W. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.023 · Cited by 13
Gene therapy for neuromuscular disorders: prospects and ethics
Ryan, M. M. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320908 · Cited by 15
Genetically modified immunomodulatory cell-based biomaterials in tissue regeneration and engineering
Jiang, Z., Fu, M., Zhu, D., Wang, X., Li, N., Ren, L., Jin, H., & Yang, G. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.05.003 · Cited by 14
Flies in the ointment: AAV vector preparations and tumor risk
Zhang, J., Yu, X., Herzog, R. W., Samulski, R. J., & Xiao, W. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.016 · Cited by 13
Krabbe Disease: Prospects of Finding a Cure Using AAV Gene Therapy
Nasir, G., Chopra, R., Elwood, F., & Ahmed, S. S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.760236 · Cited by 13
“Yet another AAV editing vector targeting the Rian locus produced HCC in all injected mice, though it is important to note that animals treated with the control vector developed HCC as well, albeit at a lower frequency (145).”
BackgroundInfluentialBouziana, S. D., & Bouzianas, D. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179518 · Cited by 15
“However, animal models have shown increased incidence of hepatocellular carcinoma after AAV liver gene transfer, which is alarming for potential vector-related tumourogenesis [73,74].”
BackgroundWang, J., Poskitt, L. E., Gallagher, J., Puffenberger, E. G., Wynn, R., Shishodia, G., Chuang, D., Beever, J. E., Hardin, D. L., Brigatti, K. W., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ads0539 · Cited by 14
The brain-joint axis: links between osteoarthritis and neurodegenerative disorders in aging
Rabie, M. A., Madry, H., Cucchiarini, M., & Sayed, N. S. E. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.023 · Cited by 17
Gene Therapy for Inherited Diseases of Liver Metabolism
Piccolo, P., & Brunetti‐Pierri, N. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.029 · Cited by 12
Treatment of metabolic disorders using genomic technologies: Lessons from methylmalonic acidemia
Venturoni, L. E., & Venditti, C. P. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12534 · Cited by 12
“Additional pre-clinical gene therapy experiments defined effective dose ranges for neonatal rescue(54) and also uncovered an untoward effect of high-dose AAV gene therapy when using cassettes that contain strong enhancers to neonatal mice, namely the late development of hepatocellular carcinoma (HCC).(85) The subseque…”
BackgroundSelf-citationAAV induces hepatic necroptosis and carcinoma in diabetic and obese mice dependent on Pebp1 pathway
Cheng, Y., Zhang, Z., Gao, P., Lai, H., Zhong, W., Feng, N., Yang, Y., Yu, H., Zhang, Y., Han, Y., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217230 · Cited by 12
“Therefore, an association between AAV and HCC in the setting of therapeutic gene delivery has remained uncertain, and the mechanisms of AAV-correlated development of HCC are still largely unknown (Valdmanis et al, 2012; Chandler et al, 2015).”
BackgroundEvaluating the Genomic Parameters Governing rAAV-Mediated Homologous Recombination
Spector, L. P., Tiffany, M. R., Ferraro, N. M., Abell, N. S., Montgomery, S. B., & Kay, M. A. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.025 · Cited by 13
Schmidt, M., Gil-Fariña, I., & Büning, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.48 · Cited by 12
Gene Therapy Medicinal Products: Non-clinical Safety Studies
Astapova, O. V., & Berchatova, A. A. (2023) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2023-11-1-329 · Cited by 12
“Однако имеются данные о том, что AAV могут интегри - роваться в геном клетки-хозяина, хотя и с очень низкой частотой [36, 37].”
Minno, G. D., Miesbach, W., Castaman, G., & Peyvandi, F. (2024) · Haematologica · doi:10.3324/haematol.2023.284622 · Cited by 21
Minno, G. D., Castaman, G., CRISTOFARO, R. D., Brunetti‐Pierri, N., Pastore, L., Castaldo, G., Trama, U., & Minno, M. N. D. D. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101011 · Cited by 12
Intrathymic AAV delivery results in therapeutic site-specific integration at TCR loci
Calabria, A., Cipriani, C., Spinozzi, G., Rudilosso, L., Esposito, S., Benedicenti, F., Albertini, A., Pouzolles, M., Luoni, M., Giannelli, S. G., et al. (2023) · Blood · doi:10.1182/blood.2022017378 · Cited by 23
AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials
Muczynski, V., & Nathwani, A. C. (2024) · Thrombosis Research · doi:10.1016/j.thromres.2020.12.033 · Cited by 11
Postnatal therapeutic approaches in genetic neurodevelopmental disorders
Levy, G., & Barak, B. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.293133 · Cited by 10
“…though AAV is mostly non-pathogenic and non-immunogenic, some studies have found evidence of hepatic genotoxicity of AAV following in vivo gene manipulation by AAV vector, resulting in hepatocellular carcinoma (Donsante et al., 2007; Chandler et al., 2015) and liver failure (Hinderer et al., 2018).”
BackgroundKashiwakura, Y., Endo, K., Ugajin, A., Kikuchi, T., Hishikawa, S., Nakamura, H., Katakai, Y., Baatartsogt, N., Hiramoto, T., Hayakawa, M., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.08.016 · Cited by 12
Senís, E., Mockenhaupt, S., Rupp, D., Bauer, T., Paramasivam, N., Knapp, B. L., Gronych, J., Große, S., Windisch, M. P., Schmidt, F., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw805 · Cited by 11
“A recent example strikingly illustrating these concerns are findings in mice that AAV vector integration into the Rian locus can cause hepatocellular carcinoma (HCC), depending on vector dose and promoter/enhancer elements (31).”
Sonogenetics in the Treatment of Chronic Diseases: A New Method for Cell Regulation
Zhu, M., Fang, Y., Sun, Y.-K., Li, S., Yu, J., Xiong, B., Wen, C., Zhou, B., Huang, B., Yin, H., et al. (2024) · Advanced Science · doi:10.1002/advs.202407373 · Cited by 14
Daly, O. M., Mahiny, A. J., Majeski, S., McClintock, K., Reichert, J., Boros, G., Szabó, G. T., Reinholz, J., Schreiner, P., Reid, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061735 · Cited by 12
AAV-based gene therapy ameliorated CNS-specific GPI defect in mouse models
Murakami, Y., Umeshita, S., Imanishi, K., Yoshioka, Y., Ninomiya, A., Sunabori, T., Likhite, S. B., Koike, M., Meyer, K., & Kinoshita, T. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101176 · Cited by 10
“10 In humans, the upregulation of delta-like homolog 1-deiodinase type 3, the orthologous locus to the mouse Rian locus, has been associated with poor survival in patients with he-patic carcinoma.”
BackgroundSynergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver
Jauze, L., Vie, M., Miagoux, Q., Rossiaud, L., Vidal, P., Montalvo-Romeral, V., Saliba, H., Jarrige, M., Polvèche, H., Nozi, J., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.172614 · Cited by 11
“…expression of the GDE transgene in liver and muscle with a dual AAV vector, the use of such a promoter was associated with an increased risk of immune response to the transgene (13, 27, 28) and the potential formation of liver tumors at high vector doses when injected in neonatal animals (29).”
BackgroundKaiser, R. A., Nicolas, C. T., Allen, K. L., Chilton, J. A., Du, Z., Hickey, R., & Lillegard, J. B. (2019) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2018.249 · Cited by 11
“could be mitigated by dose, design, and timing of administration.(18) Conversely, there are not many preclinical accounts of toxicity from in vivo lentiviral vector administration, especially in wild type animals to describe baseline toxicity of these vectors, primarily from integration and not transgene expression.”
BackgroundMinno, G. D., Spadarella, G., Maldonato, N. M., Lucia, N. D., Castaman, G., CRISTOFARO, R. D., Santoro, C., Peyvandi, F., Borrelli, A., Lupi, A., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101118 · Cited by 11
Li, Y., Xi, Z., Yu, Z., Yang, C., & Tan, C. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11352 · Cited by 11
Ryckman, A. E., Deschenes, N. M., Quinville, B. M., Osmon, K. J. L., Mitchell, M., Chen, Z., Gray, S. J., & Walia, J. S. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101168 · Cited by 9
“The LD had significantly greater GM2 storage than the heterozygotes (*p < 0.0001). hepatocellular carcinoma were the most likely cause of the liver nodules seen by Walia et al. 36,45,46 This phenomenon has not been observed with adult murine injections of AAV vectors.”
BackgroundInfluentialEmerging roles of RNA‐binding proteins in fatty liver disease
Adesanya, O. A., Das, D., & Kalsotra, A. (2024) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1840 · Cited by 11
“This oncogenic risk is, however, low with recombinant AAVs (Ferla et al., 2020), even after repeated trans-ductions in adults (Li et al., 2011; Nault et al., 2015), or transduction during the neonatal period (Chandler et al., 2015).”
BackgroundAAV-dCas9 vector unsilences paternal Ube3a in neurons by impeding Ube3a-ATS transcription
Wolter, J. M., James, L. M., Boeshore, S. L., Mao, H., McCoy, E. S., Ryan, D. F., Fragola, G., Taylor‐Blake, B., Stein, J. L., & Zylka, M. J. (2025) · Communications Biology · doi:10.1038/s42003-025-08794-2 · Cited by 9
Recent Advances in Gene Therapy for Hemophilia
Pang, X., Fu, J., Zhou, Z., Tang, N., Lau, C., Wen, Y., Chen, P., Zhao, J., & Xue, H. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251378455 · Cited by 12
“Long-term animal studies, 107 ultra-deep sequencing analyses, 108 and clinical case reports 109 collectively indicate that AAV exhibits a low yet non-negligible oncogenic risk.”
Gene Therapy Strategies for Hepatocellular Carcinoma (HCC): Current Landscape and Future Directions
Ermi, A. G., Younis, R. M., Rodriguez, K., & Sarkar, D. (2025) · Cancers · doi:10.3390/cancers17223608 · Cited by 10
“Many factors, such as vector size limited to 4.5 kb, enhancer/promoter selection, and timing of delivery, are critical in mitigating these risks [130].”
InfluentialKlapwijk, J. C., Río-Espínola, A. D., Libertini, S., Collin, P., Fellows, M. D., Jobling, S., Lynch, A. M., Martus, H., Vickers, C. A., Zeller, A., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.033 · Cited by 9
Matsuzaka, Y., Hirai, Y., Hashido, K., & Okada, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031551 · Cited by 9
In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene
Giorgi, M. D., Park, S. H., Castoreno, A. B., Cao, M., Hurley, A. E., Saxena, L., Chuecos, M. A., Walkey, C. J., Doerfler, A. M., Furgurson, M. N., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3920 · Cited by 11
AAV2 and Hepatocellular Carcinoma
Nault, J., Datta, S., Imbeaud, S., Franconi, A., Mallet, M., Couchy, G., Letouzé, É., Pilati, C., Verret, B., Blanc, J., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.002 · Cited by 10
“…role of AAV2 in human hepatocytes and in human cancers; (2) in our study, AAV2 insertions are clo-naly selected in the human tumors, and because they are identified in the tumors, per definition, 16,17 ; and (5) most of HCC with AAV2 insertion are developed on noncirrhotic liver without etiology.”
Kim, Y.-D., Park, T., Singh, B., Cho, K.-S., Sangshetti, J. N., Choi, Y., Arote, R. B., & Cho, C. (2016) · Journal of Materials Chemistry B · doi:10.1039/c5tb01799h · Cited by 10
Brunetti‐Pierri, N., & Newsome, P. N. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.006 · Cited by 9
Mutagenesis and Carcinogenesis Risk Evaluation for AAV and Lentiviral Gene Therapies
Parman, T., Pizzurro, D. M., Lucas, J., & Peng, Z. (2025) · International Journal of Toxicology · doi:10.1177/10915818251318248 · Cited by 9
Gorder, L. V., Doshi, B. S., Willis, E., Nichols, T. C., Cook, E., Everett, J. K., Merricks, E. P., Arruda, V. R., Bushman, F. D., Callan, M. B., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101159 · Cited by 9
“3,4 7 In addition, 2 adult hemophilia A (HA) research colony dogs treated with AAV vectors showed an increase in transgene factor VIII (FVIII) levels over time.”
Liver gene transfer for metabolite detoxification in inherited metabolic diseases
D’Alessio, A. M., Boffa, I., Stefano, L. D., Soria, L. R., & Brunetti‐Pierri, N. (2024) · FEBS Letters · doi:10.1002/1873-3468.14957 · Cited by 14
Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
Holzwarth, D., Calaminus, G., Friese, J., Sejersen, T., Büning, H., John-Neek, P., Bastone, A. L., Rothe, M., Mansfield, K. G., Libertini, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.025 · Cited by 9
“12,15 20 Evidence of rAAV-induced tumorigenicity in humans is theoretical as of the date of this publication; however, insertional oncogenesis should be investigated for patients treated with rAAVs should a tumor appear.”
GeIST: a pipeline for mapping integrated DNA elements
LaFave, M. C., Varshney, G. K., & Burgess, S. M. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv350 · Cited by 8
“For AAV data, GeIST makes use of an extra Perl script and an adjusted trimming strategy to account for the variable region of the inverted terminal repeat used for amplification (Linden et al. , 1996).”
MethodInfluentialSelf-citationGene Therapy for Hemophilia A: Where We Stand
Zhou, M., Hu, Z., Zhang, C., Wu, L., Li, Z., & Liang, D. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200806110849 · Cited by 9
Kang, J., Hang, L., Zheng, W., Luo, J., Zhang, X., Song, Y., & Liu, A. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12532 · Cited by 9
Gene Delivery into Cells and Tissues
Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00035-5 · Cited by 10
Kim, M. S., Park, M. H., Park, J. E., Yun, J. I., Choi, J. H., Lee, E., & Lee, S. T. (2019) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-019-00326-7 · Cited by 9
Iizuka, S., Sakurai, F., Tachibana, M., Ohashi, K., & Mizuguchi, H. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.07.001 · Cited by 8
“Second, AAV has been reported to cause hepatocellular carcinoma following neonatal administration due to the insertional mutagenesis.(30,31) This novel Ad vector, Ad-E4-122aT, exhibits a safer transduction profile and sustained transgene expression following systemic administration.”
BackgroundTopics in AAV integration come front and center at ASGCT AAV Integration Roundtable
Sabatino, D. E., & McCarty, D. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.024 · Cited by 8
Althubity, A. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13745 · Cited by 8
“Foundational work on vector design and dosing has also highlighted safety principles to minimize hepatic genotoxicity in gene‑delivery programs (71).”
Doustmihan, A., Akbari, M., Jaymand, M., Liu, G., & Jahanban‐Esfahlan, R. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.115098 · Cited by 7
Structural basis of liver de-targeting and neuronal tropism of CNS-targeted AAV capsids
Brittain, T. J., Jang, S., Coughlin, G. M., Hoang, J. D., Barcelona, B. H., Giriat, I., Ristic, F., Appling, N., Chossis, C. P., Shay, T. F., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.030 · Cited by 11
Frisch, J., & Cucchiarini, M. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0106 · Cited by 9
“Yet, although first considered safer than the integrative retro-/lentiviral vectors, rAAV have recently raised concerns regarding their possible potential for oncogenic insertional mutagenesis leading to hepatocellular carcinoma [251,252].”
Zhang, L., Yates, B., Murphy, R., Liu, S., Xie, L. Y., Handyside, B., Sihn, C., Bouwman, T., Galicia, N., Tan, D., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.002 · Cited by 8
Isling: A Tool for Detecting Integration of Wild-Type Viruses and Clinical Vectors
Scott, S., Hallwirth, C. V., Hartkopf, F., Grigson, S. R., Jain, Y., Alexander, I. E., Bauer, D. C., & Wilson, L. O. W. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167408 · Cited by 8
Genomic Designs of rAAVs Contribute to Pathological Changes in the Livers and Spleens of Mice
Mulcrone, P. L., Zhang, J., Pride, P. M., Lam, A. K., Frabutt, D. A., Ball-Kell, S. M., & Xiao, W. (2022) · Advances in Cell and Gene Therapy · doi:10.1155/2022/6807904 · Cited by 7
“Interestingly, the same effect was not seen in MMA mice injected with an AAV8-MUT vector that housed the α-1 antitrypsin (AAT) promoter, a weak liver-specific promoter [13].”
BackgroundThe clinical toxicity of advanced therapy medicinal products
Henderson, F. J. H., & Hill, S. L. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70104 · Cited by 6
“122 Although several AAV-based GTMPs have been approved, safety concerns persist.”
Mnyandu, N., Limani, S. W., Ely, A., Wadee, R., Arbuthnot, P. B., & Maepa, M. B. (2025) · Virology Journal · doi:10.1186/s12985-025-02662-5 · Cited by 8
Opportunities and Challenges of Fetal Gene Therapy
Jeanne, M., & Chung, W. K. (2025) · Prenatal Diagnosis · doi:10.1002/pd.6809 · Cited by 7
“Preclinical studies have reported the development of carcinoma in fetal mice after injection with lentivirus vectors but also with non‐integrating vectors such as AAV [33–35].”
Flory, E., Walter, M., Closson-Carella, V., Celis, P., Schuessler‐Lenz, M., & Reischl, I. G. (2025) · Human Gene Therapy · doi:10.1177/10430342251366314 · Cited by 6
“21 22 – 27 The most prominent example of AAV-GT-related HCC is the neonatal model in which HCC was found in > 70% of mice following a single intrahepatic injection of a rAAV vector.”
Kujala, A., Valkonen, E., Sallinen, H., Tuppurainen, L., Laakso, H., Ylä‐Herttuala, E., Liimatainen, T., Kujala, J., Jokelainen, O., Sironen, R. K., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1018208 · Cited by 6
“In general, AAV vectors are considered to be well tolerated and highly efficient viral vectors, and studies with longitudinal follow-ups have not shown significant adverse effects with commonly used viral doses (21).”
BackgroundSondhi, D., Kaminsky, S. M., Rosenberg, J. B., Rostami, M. R., Hackett, N. R., & Crystal, R. G. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.182 · Cited by 6
Walia, J. S., Osmon, K. J. L., Thompson, P., Woodley, E., Karumuthil‐Melethil, S., Heindel, C., Keimel, J. G., Kaemmerer, W. F., & Gray, S. J. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210916153051 · Cited by 7
Gene Therapy in Pediatric Liver Disease
Muro, A. F., D’Antiga, L., & Mingozzi, F. (2019) · Springer eBooks · doi:10.1007/978-3-319-96400-3_44 · Cited by 7
Gene delivery into cells and tissues
Nelson, C. E., Duvall, C. L., Prokop, A., Gersbach, C. A., & Davidson, J. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00030-7 · Cited by 9
Pompe disease: how to solve many problems with one solution
Puertollano, R., & Raben, N. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.52 · Cited by 8
“The rAAV technology has been successfully tested in preclinical studies and applied in the clinic for a variety of disorders (11,12), including Pompe disease.”
BackgroundRussell, C. B., Vettermann, C., Agarwal, S., Witt, E., Clark, W. T., Arens, J., Fronza, R., Obrochta, K. M., Kasprzyk, T., Robinson, T. M., et al. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.236 · Cited by 5
Transforming Hemophilia Management: Lessons from Gene Therapy Clinical Trials
Hussain, M. S., Maqbool, M., Arab, M. M., Rana, A. J., Ashique, S., Khan, Y., Jakhmola, V., & Gupta, G. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01464-y · Cited by 6
Antal, R., Benyó, Z., Nagy, Z. Z., Kovács, I., Fekete, J. T., Győrffy, B., & Kovács, K. A. (2025) · GeroScience · doi:10.1007/s11357-025-01921-1 · Cited by 7
Limani, S. W., Mnyandu, N., Ely, A., Wadee, R., Kramvis, A., Arbuthnot, P. B., & Maepa, M. B. (2021) · Viruses · doi:10.3390/v13112247 · Cited by 5
Metadata
- Authors
- Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., & Venditti, C. P.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-01-20
- Volume
- 125
- Issue
- 2
- Pages
- 870-880
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4319425
- OpenAlex
- W2133112334
- Cited by
- 403
- References
- 63
- Citations by year
- 2026: 28 · 2025: 42 · 2024: 40 · 2023: 38 · 2022: 36 · 2021: 32 · 2020: 45 · 2019: 30 · 2018: 26 · 2017: 32 · 2016: 31 · 2015: 22
- FWCI
- 25.28
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- adeno-associated virus, gene therapy vectors, hepatocellular carcinoma, genotoxicity, AAV integration, microRNA overexpression, RTL1, vector dose
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Mutant Strains, Pregnancy Proteins, Transduction, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.